HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s share price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $3.10 and traded as low as $3.03. HLS Therapeutics shares last traded at $3.05, with a volume of 2,220 shares.
Analyst Ratings Changes
Separately, Raymond James Financial raised HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating. According to data from MarketBeat.com, the stock has an average rating of “Strong Buy”.
Read Our Latest Stock Report on HLTRF
HLS Therapeutics Price Performance
The stock’s 50-day moving average price is $2.84 and its 200 day moving average price is $3.10.
HLS Therapeutics Company Profile
HLS Therapeutics Inc is a specialty pharmaceutical company focused on acquiring, licensing, developing and commercializing prescription medicines. Rather than primarily discovering new drugs, the company generally builds value by obtaining rights to established or differentiated pharmaceutical products and supporting their regulatory approval, market access and commercial distribution.
The company’s activities have centered on specialty-care and hospital-related therapies, including products for central nervous system and cardiovascular conditions.
Featured Stories
- Five stocks we like better than HLS Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
